These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33074778)

  • 1. Lipid-lowering therapies in peripheral artery disease: A review.
    Skeik N; Nowariak ME; Smith JE; Alexander JQ; Manunga JM; Mirza AK; Sullivan TM
    Vasc Med; 2021 Feb; 26(1):71-80. PubMed ID: 33074778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target?
    Rymer JA; Swaminathan RV; Aday AW; Patel MR; Gutierrez JA
    Curr Cardiol Rep; 2021 Jan; 23(3):13. PubMed ID: 33483872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of statins in patients with peripheral artery disease.
    Corrado E; Mignano A; Coppola G
    Trends Cardiovasc Med; 2020 Jul; 30(5):257-262. PubMed ID: 31307839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews.
    Dugré N; Lindblad AJ; Perry D; Allan GM; Braschi É; Falk J; Froentjes L; Garrison SR; Kirkwood JEM; Korownyk CS; McCormack JP; Moe SS; Paige A; Potter J; Thomas BS; Ton J; Young J; Weresch J; Kolber MR
    Can Fam Physician; 2023 Oct; 69(10):701-711. PubMed ID: 37833094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Update on lipid lowering therapy in peripheral artery disease].
    Mühlberg KS
    Dtsch Med Wochenschr; 2023 Nov; 148(22):1406-1411. PubMed ID: 37918423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering treatment in peripheral artery disease.
    Katsiki N; Giannoukas AD; Athyros VG; Mikhailidis DP
    Curr Opin Pharmacol; 2018 Apr; 39():19-26. PubMed ID: 29413998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
    Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease.
    Belch JJF; Brodmann M; Baumgartner I; Binder CJ; Casula M; Heiss C; Kahan T; Parini P; Poredos P; Catapano AL; Tokgözoğlu L
    Vasa; 2021 Nov; 50(6):401-411. PubMed ID: 34743585
    [No Abstract]   [Full Text] [Related]  

  • 12. Proprotein Convertase Subtilism/Kexin 9 (PCSK9) Inhibitors: Adding to the Armamentarium of the Primary Care Physician.
    Coy K; Stys A; Stys T; DeVries J
    S D Med; 2021 Oct; 74(10):454-456. PubMed ID: 34995425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement.
    Belch JJF; Brodmann M; Baumgartner I; Binder CJ; Casula M; Heiss C; Kahan T; Parini P; Poredos P; Catapano AL; Tokgözoğlu L
    Atherosclerosis; 2021 Dec; 338():55-63. PubMed ID: 34763902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or Cerebrovascular Disease.
    Deo SV; McAllister D; LaForest S; Altarabsheh S; Elgudin YE; Dunlay S; Singh S; Parikh S; Sattar N; Pell JP
    Am J Cardiovasc Drugs; 2023 May; 23(3):311-321. PubMed ID: 36947397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease.
    Annex BH; Cooke JP
    Circ Res; 2021 Jun; 128(12):1944-1957. PubMed ID: 34110899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.